Objectives To detection of chlamydia pneumoniae (Cpn) DNA in the circulating mononuclear cell fractions of coronary heart disease and to investigate the association between infection with chlamydia pneumoniae and coro...Objectives To detection of chlamydia pneumoniae (Cpn) DNA in the circulating mononuclear cell fractions of coronary heart disease and to investigate the association between infection with chlamydia pneumoniae and coronary heart disease (CHD) and prospectively whether blood - based nes- ted polymerase chain reaction(nPCR ) is useful in i- dentifying Cpn infection. Methods The peripheral blood mononuclear cell (PBMC) Cpn DNA was exam- ined using nPCR technique and confirmed by electro- phoresis in 150 patients with CHD. Select 55 patients with clinical suspected CHD but angiography result are normal as control group (CG). Then we conducted a prospective , randomized, double - blind, placebo - controlled study of 6 months of azithromycin and place- bo treatment in CHD group. Patients with Cpn DNA positive were then randomized to receive azithromycin or placebo. After treatment blood sample were collect- ed for repeated measurement . Results Chlamydia pneumoniae DNA was detected in 49(32. 7% ) of 150 persons with CHD and in 1 (1. 8% ) of 55 persons with control group,odds ratio 26. 2, 95% confidence interva 13. 52 - 194. 98. The positivity rates of nPCR in CHD groups were higher than those in control group. 16 ca- ses (29. 1%) in latent coronary heart diseases (LCHD)group , 19 cases (39.6%) in unstable angi- na(UAP) group ,and 14 cases (29.9% ) in acute my- ocardial infarction (AMI) group were Cpn positive by nPCR. There were no significant difference among in AMI^UAP and LCHD group. There were significiantdifference in Cpn DNA negative rates after the azithro- mycin and the placebo treatment. Conclusions Chlamydia pneumoniae is present in PBMC of a signifi- cant proportion of persons with CHD. The potential role of chlamydia pneumoniae in coronary atherosclerosis may therefore be more related to acceleration of disease or systemic effects by persistent infection than to sud- den initiation of progressive coronary artery disease by acute infection. The detection of Cpn DNA in PBMC with nPCR may be of great value for identifying Cpn carriers and for monitoring antichlamydial therapy.展开更多
文摘Objectives To detection of chlamydia pneumoniae (Cpn) DNA in the circulating mononuclear cell fractions of coronary heart disease and to investigate the association between infection with chlamydia pneumoniae and coronary heart disease (CHD) and prospectively whether blood - based nes- ted polymerase chain reaction(nPCR ) is useful in i- dentifying Cpn infection. Methods The peripheral blood mononuclear cell (PBMC) Cpn DNA was exam- ined using nPCR technique and confirmed by electro- phoresis in 150 patients with CHD. Select 55 patients with clinical suspected CHD but angiography result are normal as control group (CG). Then we conducted a prospective , randomized, double - blind, placebo - controlled study of 6 months of azithromycin and place- bo treatment in CHD group. Patients with Cpn DNA positive were then randomized to receive azithromycin or placebo. After treatment blood sample were collect- ed for repeated measurement . Results Chlamydia pneumoniae DNA was detected in 49(32. 7% ) of 150 persons with CHD and in 1 (1. 8% ) of 55 persons with control group,odds ratio 26. 2, 95% confidence interva 13. 52 - 194. 98. The positivity rates of nPCR in CHD groups were higher than those in control group. 16 ca- ses (29. 1%) in latent coronary heart diseases (LCHD)group , 19 cases (39.6%) in unstable angi- na(UAP) group ,and 14 cases (29.9% ) in acute my- ocardial infarction (AMI) group were Cpn positive by nPCR. There were no significant difference among in AMI^UAP and LCHD group. There were significiantdifference in Cpn DNA negative rates after the azithro- mycin and the placebo treatment. Conclusions Chlamydia pneumoniae is present in PBMC of a signifi- cant proportion of persons with CHD. The potential role of chlamydia pneumoniae in coronary atherosclerosis may therefore be more related to acceleration of disease or systemic effects by persistent infection than to sud- den initiation of progressive coronary artery disease by acute infection. The detection of Cpn DNA in PBMC with nPCR may be of great value for identifying Cpn carriers and for monitoring antichlamydial therapy.
